GSK's Tyverb only to be used in clinical trials for breast cancer patients, says NICE
This article was originally published in Scrip
NICE, the National Institute for health and Clinical Excellence, still says that GlaxoSmithKline's anticancer Tyverb (lapatinib) is not value for money and that it should only be used to treat NHS patients in England and Wales with advanced or metastatic breast cancer as part of a clinical trial.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.